Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM3G4JD)

• Drug Name: CBD cannabis derivative Drug Info
• Synonyms: AC1L5AAH; (6,6-dimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) 5-(diethylamino)pentanoate

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 173616
  TTD Drug ID: DM3G4JD

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Antagonist	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cannabinoid receptor 1 (CB1)	DTT	CNR1	2.907	4.667	2.982	3.678

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cannabinoid receptor 1 (CB1)	DTT	CNR1	5.59E-02	-0.22	-0.45
Cannabinoid receptor 1 (CB1)	DTT	CNR1	7.68E-01	-0.06	-0.46

References

• [1] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.